Products for Research Use Only
RegisterLogin

Sotatercept (mIgG2a)

CAT: 0804-HY-P99590A-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99590A-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Sotatercept (mIgG2a) (RAP-011), the murine homolog of Sotatercept (ACE-011) , is a soluble activin receptor type IIA (ActRIIA) ligand trap. Sotatercept (mIgG2a) inhibits the binding of activin A and other members of the TGF-β superfamily (such as Activin A/B, GDF11 and BMP9/10) to their receptors by combining and neutralizing them, thereby regulating cell proliferation and differentiation. Sotatercept (mIgG2a) mainly inhibits the SMAD2/3 signaling pathway, and can be used in various diseases such as chronic kidney disease. Sotatercept (mIgG2a) reduces the expression of erythropoietic hepcidin (ERFE), regulates iron metabolism, and promotes red blood cell production. Sotatercept (mIgG2a) has a dual effect of promoting bone formation (anabolic) and inhibiting bone resorption (catabolic)[2][3][4].
Product Name Alternative
RAP-011
UNSPSC
12352203
Target
TGF-beta/Smad; TGF-β Receptor
Type
Inhibitory Antibodies
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Applications
Neuroscience-Neuromodulation
Field of Research
Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/sotatercept-migg2a.html
Purity
99.93
Solubility
10 mM in DMSO
Smiles
[Sotatercept(mIgG2a)]
Molecular Weight
(79.67 kDa)
References & Citations
[1]Morse A, et al. RAP-011 augments callus formation in closed fractures in rats. J Orthop Res. 2016 Feb;34 (2) :320-30.|[2]Langdon JM, et al. RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice. Am J Hematol. 2015 Jan;90 (1) :8-14. |[3]Agapova OA, et al. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int. 2016 Jun;89 (6) :1231-43. |[4]De Rosa G, et al. RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway. Int J Mol Sci. 2020 Aug 4;21 (15) :5577.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched

Related Products

CatalogName
HY-P99590-01Sotatercept
HY-P99720ALuspatercept (mIgG2a)
HY-RS08447MIGA2 Human Pre-designed siRNA Set A
HY-P705080-01SARS-CoV-2 S RBD (Biotinylated, HEK293, mIgG1-Avi)

Alternative Products

CatalogName
M36791-01Sotatercept
GTR18578442-01Sotatercept Antibody
WA3559Research Grade Sotatercept
GTR18697457-01Sotatercept Monoclonal Antibody
ICH5877-1mgSotatercept Biosimilar - Research Grade
E55B1174Sotatercept (Reference antibody)
ptrioz-migg2apTRIOZ-mIgG2a
F2093-1Anti-TGF-β Receptor Antibody (Sotatercept)
pfuse-mg2afc2pFUSE-mIgG2A-Fc2
hcd20-mab10-3Anti-hCD20-mIgG2a

Popular Products